Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 6:54 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 457–480 of 33,183 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Placebo, Clear all

Conditions: Constipation, Chronic Idiopathic Constipation, CIC
Interventions: BLI400 Laxative, BLI400 Placebo; Drug
Lead sponsor: Braintree Laboratories; Industry
Eligibility: 18 Years and older
Enrollment: 1,020 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 51
States / cities: Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 43 more

Conditions: HIV Risk Reduction, Attention Control Case Management
Interventions: Maybe, Maybe Not, Comprehensive Risk Counseling and Services; Behavioral
Lead sponsor: University of South Florida; Other
Eligibility: 18 Years and older
Enrollment: 351 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2020
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Alcoholism, Depression
Interventions: NALTREXONE, Placebo; Drug
Lead sponsor: US Department of Veterans Affairs; Federal
Eligibility: 55 Years and older
Enrollment: 74 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2005
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Type 1 Diabetes Mellitus
Interventions: Pramlintide acetate, Placebo, Lispro insulin U-100, Regular insulin U-100; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 3
States / cities: Chula Vista, California • Portland, Oregon • Chattanooga, Tennessee

Conditions: Surgical Wounds, Mohs Surgery
Interventions: Topical Timolol, Normal Saline; Drug
Lead sponsor: Geisinger Clinic; Other
Eligibility: 18 Years and older
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Danville, Pennsylvania

Conditions: First Trimester Abortion
Interventions: Azithromycin, Doxycycline, Metronidazole, Placebo; Drug
Lead sponsor: Medstar Health Research Institute; Other
Eligibility: 18 Years and older · Female only
Enrollment: 181 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2017
U.S. locations: 2
States / cities: Washington D.C., District of Columbia • Silver Spring, Maryland

Conditions: Myocardial Infarct
Interventions: RNS60, Placebo; Drug
Lead sponsor: Revalesio Corporation; Industry
Eligibility: 18 Years to 55 Years · Male only
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Abdominal Abscess
Interventions: Gentamicin Sulfate Inj 20mg/2ml vial for injection, Clindamycin phosphate 6 mg/1ml for injection, Placebo; Drug · Other
Lead sponsor: University of Iowa; Other
Eligibility: 18 Years to 80 Years
Enrollment: 2 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Iowa City, Iowa

Conditions: ADHD
Interventions: Lisdexamfetamine dimesylate (LDX), Placebo; Drug
Lead sponsor: Shire; Industry
Eligibility: 6 Years to 17 Years
Enrollment: 276 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 4
States / cities: Rolling Hills Estates, California • South Miami, Florida • Overland Park, Kansas + 1 more

Conditions: Nausea, Vomiting
Interventions: Aprepitant, Scopolamine; Drug
Lead sponsor: Drexel University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 115 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2010
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Type 1 Diabetes Mellitus
Interventions: DHA Treatment, Placebo for DHA; Dietary Supplement
Lead sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); NIH
Eligibility: Up to 5 Months
Enrollment: 99 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2013
U.S. locations: 9
States / cities: Los Angeles, California • Orange, California • San Francisco, California + 6 more

Conditions: Restless Legs Syndrome
Interventions: GEn (XP13512/GSK1838262), Placebo; Drug
Lead sponsor: XenoPort, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 217 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Inflammation at Mini-screw Insertion Site, Mobility, Mini-screw
Interventions: Amoxicillin, Placebo oral capsule; Drug
Lead sponsor: St. Louis University; Other
Eligibility: 12 Years and older
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Diabetes Mellitus, Type 2
Interventions: PF-05175157, Placebo; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 31 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012
U.S. locations: 1
States / cities: South Miami, Florida

Conditions: Healthy
Interventions: GSI-953; Drug
Lead sponsor: Wyeth is now a wholly owned subsidiary of Pfizer; Industry
Eligibility: 65 Years and older
Enrollment: 49 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2009
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Alcohol Use Disorder (AUD), Obesity (BMI Equal to or >30)
Interventions: Placebo, Semaglutide 1.0 mg, Semaglutide 2.0 mg; Other · Drug
Lead sponsor: Yale University; Other
Eligibility: 18 Years to 68 Years
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Parkinson's Disease
Interventions: Placebo, IPX066 95 mg LD, IPX066 145 mg LD, IPX066 195 mg LD, IPX066 245 mg LD; Drug
Lead sponsor: Impax Laboratories, LLC; Industry
Eligibility: 30 Years and older
Enrollment: 381 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 27
States / cities: Birmingham, Alabama • Phoenix, Arizona • Garden Grove, California + 22 more

Conditions: Alcohol Use, Unspecified
Interventions: Placebo, Alcohol; Drug
Lead sponsor: Mark Fillmore; Other
Eligibility: 21 Years to 35 Years · Female only
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2024
U.S. locations: 1
States / cities: Lexington, Kentucky

Conditions: Diabetes Mellitus Type 1, Autoimmune Diabetes
Interventions: Insulin, Lansoprazole, Sitagliptin, Diamyd, GAD65 (Diamyd); Drug · Biological
Lead sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); NIH
Eligibility: 16 Years to 30 Years
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Vaginal Diseases
Interventions: Placebo Vaginal Insert; Other
Lead sponsor: CONRAD; Other
Eligibility: 18 Years to 50 Years · Female only
Enrollment: 49 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Norfolk, Virginia

Conditions: Moderate to Severe Chronic Pain
Interventions: NKTR-181, Oxycodone IR; Drug
Lead sponsor: Nektar Therapeutics; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 8 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: Richmond, Virginia

Conditions: Cognitive Impairment, Sleep Quality
Interventions: Nicotinamide riboside, Placebo; Dietary Supplement
Lead sponsor: State University of New York at Buffalo; Other
Eligibility: 65 Years to 85 Years
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2027
U.S. locations: 3
States / cities: Buffalo, New York

Conditions: Schizophrenia
Interventions: memantine HCl; Drug
Lead sponsor: Forest Laboratories; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 138 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2005
U.S. locations: 13
States / cities: National City, California • San Diego, California • Miami, Florida + 10 more

Conditions: Otitis Media in Patients With Tympanostomy Tubes
Interventions: Ciprofloxacin 0.3%/dexamethasone 0.1% sterile otic suspension, CIPRODEX® (ciprofloxacin 0.3%/dexamethasone 0.1%), Placebo Sterile Otic Suspension; Drug
Lead sponsor: Par Pharmaceutical, Inc.; Industry
Eligibility: 6 Months to 12 Years
Enrollment: 203 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 23
States / cities: Birmingham, Alabama • Mesa, Arizona • Phoenix, Arizona + 17 more

Search by objective public record fields.

BLI400-302: A Safety and Efficacy Evaluation of BLI400 Laxative in Constipated Adults

Disclosure to Family

Treating Alcohol Use In Older Adults With Depression

Effect of a Fixed Pramlintide: Insulin Dose Ratio on Postprandial Glucose in Type 1 Diabetes Mellitus

The Effects of Timolol On Healing and Cosmesis of Mohs Scalp Wounds: An Open Label Trial

A Randomized Controlled Trial of Three Antibiotic Regimens for First Trimester Abortions

Safety and Tolerability of RNS60 Given by IV to Healthy Subjects

Antibiotic Irrigations for Intra-Abdominal Drains

Double-blind, Placebo-controlled, Randomised Withdrawal, Extension, Safety and Efficacy Study of LDX in Children and Adolescents Aged 6-17

Comparison of Aprepitant Versus Aprepitant and Transdermal Scopolamine for Preventing Postoperative Nausea and Vomiting

Nutritional Intervention to Prevent Diabetes

Dose-Response and Pharmacokinetics of Gabapentin Enacarbil (GEn [XP13512 / GSK1838262]) in Restless Legs Syndrome

Antibiotics Prior to Mini-screw Implant Insertion

A Study To Evaluate The Effects Of PF-05175157 In Healthy Volunteers

Study Evaluating Multiple Doses Of GSI-953 Within The Elderly Population

Semaglutide Dose Effects on Metabolic and Stress Hormone, Craving and Alcohol Use Outcomes

A Study To Evaluate The Safety And Efficacy Of IPX066 In Subjects With Parkinson's Disease

Estradiol Effects on Alcohol Across the Menstrual Cycle

Novel Therapy to Preserve Beta Cell Function in New Onset Type 1 Diabetes

Assessing the Disintegration, Safety, and Acceptability of Placebo Vaginal Inserts for the Delivery of Vaginal Products

A Study Using fMRI Imaging to Evaluate the Effect of NKTR-181 on Brain Activity in Healthy, Non-physically Dependent Recreational Opioid Users.

Benefits of Nicotinamide Riboside Upon Cognition and Sleep

Evaluation of the Safety and Efficacy of Memantine as Adjunctive Treatment in Schizophrenia Patients

Bioequivalence of Two Ciprofloxacin 0.3%/Dexamethasone 0.1% Sterile Otic Suspensions in Otitis Media in Children With Tympanostomy Tubes